Tigecycline activity against metallo-β-lactamase-producing bacteria

Backgound: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Simit Kumar, Maitreyi Bandyopadhyay, Soma Mondal, Nupur Pal, Tapashi Ghosh, Manas Bandyopadhyay, Parthajit Banerjee
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2013
Materias:	gram-negative bacteria metallo-β-lactamases tigecycline Medicine R
Acceso en línea:	https://doaj.org/article/a6b8f330b4d942758079763c30e2bdcc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6b8f330b4d942758079763c30e2bdcc
record_format	dspace
spelling	oai:doaj.org-article:a6b8f330b4d942758079763c30e2bdcc2021-12-02T16:34:41ZTigecycline activity against metallo-β-lactamase-producing bacteria2231-07702249-446410.4103/2231-0770.120500https://doaj.org/article/a6b8f330b4d942758079763c30e2bdcc2013-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.120500https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Backgound: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many studies have demonstrated the activity of tigecycline against ESBL-producing Enterobacteriaceae, its activity is not well-defi ned against micro-organisms producing metallo-β-lactamases (MBLs), as there are only a few reports and the number of isolates tested is limited. Aims: The aim of the present study was to evaluate the activity of tigecycline against MBL-producing bacterial isolates. Materials and Methods: The isolates were tested for MBL production by (i) combined-disk test, (ii) double disc synergy test (DDST), (iii) susceptibility to aztreonam (30 μg) disk. Minimum inhibitory concentration to tigecycline was determined according to agar dilution method as per Clinical Laboratory Standards Institute (CLSI) guidelines. Disc diffusion susceptibility testing was also performed for all these isolates using tigecycline (15 μg) discs. Results: Among the total 308 isolates included in the study, 99 were found to be MBL producers. MBL production was observed mostly in isolates from pus samples (40.47%) followed by urine (27.4%) and blood (13.09%). MBL production was observed in E. coli (41.48%), K. pneumoniae (26.67%), Proteus mirabilis (27.78%), Citrobacter spp. (41.67%), Enterobacter spp. (25.08%), and Acinetobacter spp. (27.27%). The result showed that tigecycline activity was unaffected by MBL production and it was showed almost 100% activity against all MBL-producing isolates, with most of the isolates exhibiting an MIC ranging from 0.25-8 μg/ml, except 2 MBL-producing E. coli isolates who had an MIC of 8 μg/ml. Conclusion: To conclude, tigecycline was found to be highly effective against MBL-producing Enterobacteriaceae and acinetobacter isolates, but the presence of resistance among organisms, even before the mass usage of the drug, warrants the need of its usage as a reserve drug. The study also found that the interpretative criteria for the disc diffusion method, recommended by the FDA, correlates well with the MIC detection methods. So, the microbiology laboratories might use the relatively easier method of disc diffusion, as compared to the comparatively tedious method of MIC determination.Simit KumarMaitreyi BandyopadhyaySoma MondalNupur PalTapashi GhoshManas BandyopadhyayParthajit BanerjeeThieme Medical and Scientific Publishers Pvt. Ltd.articlegram-negative bacteriametallo-β-lactamasestigecyclineMedicineRENAvicenna Journal of Medicine, Vol 03, Iss 04, Pp 92-96 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	gram-negative bacteria metallo-β-lactamases tigecycline Medicine R
spellingShingle	gram-negative bacteria metallo-β-lactamases tigecycline Medicine R Simit Kumar Maitreyi Bandyopadhyay Soma Mondal Nupur Pal Tapashi Ghosh Manas Bandyopadhyay Parthajit Banerjee Tigecycline activity against metallo-β-lactamase-producing bacteria
description	Backgound: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many studies have demonstrated the activity of tigecycline against ESBL-producing Enterobacteriaceae, its activity is not well-defi ned against micro-organisms producing metallo-β-lactamases (MBLs), as there are only a few reports and the number of isolates tested is limited. Aims: The aim of the present study was to evaluate the activity of tigecycline against MBL-producing bacterial isolates. Materials and Methods: The isolates were tested for MBL production by (i) combined-disk test, (ii) double disc synergy test (DDST), (iii) susceptibility to aztreonam (30 μg) disk. Minimum inhibitory concentration to tigecycline was determined according to agar dilution method as per Clinical Laboratory Standards Institute (CLSI) guidelines. Disc diffusion susceptibility testing was also performed for all these isolates using tigecycline (15 μg) discs. Results: Among the total 308 isolates included in the study, 99 were found to be MBL producers. MBL production was observed mostly in isolates from pus samples (40.47%) followed by urine (27.4%) and blood (13.09%). MBL production was observed in E. coli (41.48%), K. pneumoniae (26.67%), Proteus mirabilis (27.78%), Citrobacter spp. (41.67%), Enterobacter spp. (25.08%), and Acinetobacter spp. (27.27%). The result showed that tigecycline activity was unaffected by MBL production and it was showed almost 100% activity against all MBL-producing isolates, with most of the isolates exhibiting an MIC ranging from 0.25-8 μg/ml, except 2 MBL-producing E. coli isolates who had an MIC of 8 μg/ml. Conclusion: To conclude, tigecycline was found to be highly effective against MBL-producing Enterobacteriaceae and acinetobacter isolates, but the presence of resistance among organisms, even before the mass usage of the drug, warrants the need of its usage as a reserve drug. The study also found that the interpretative criteria for the disc diffusion method, recommended by the FDA, correlates well with the MIC detection methods. So, the microbiology laboratories might use the relatively easier method of disc diffusion, as compared to the comparatively tedious method of MIC determination.
format	article
author	Simit Kumar Maitreyi Bandyopadhyay Soma Mondal Nupur Pal Tapashi Ghosh Manas Bandyopadhyay Parthajit Banerjee
author_facet	Simit Kumar Maitreyi Bandyopadhyay Soma Mondal Nupur Pal Tapashi Ghosh Manas Bandyopadhyay Parthajit Banerjee
author_sort	Simit Kumar
title	Tigecycline activity against metallo-β-lactamase-producing bacteria
title_short	Tigecycline activity against metallo-β-lactamase-producing bacteria
title_full	Tigecycline activity against metallo-β-lactamase-producing bacteria
title_fullStr	Tigecycline activity against metallo-β-lactamase-producing bacteria
title_full_unstemmed	Tigecycline activity against metallo-β-lactamase-producing bacteria
title_sort	tigecycline activity against metallo-β-lactamase-producing bacteria
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2013
url	https://doaj.org/article/a6b8f330b4d942758079763c30e2bdcc
work_keys_str_mv	AT simitkumar tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT maitreyibandyopadhyay tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT somamondal tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT nupurpal tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT tapashighosh tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT manasbandyopadhyay tigecyclineactivityagainstmetalloblactamaseproducingbacteria AT parthajitbanerjee tigecyclineactivityagainstmetalloblactamaseproducingbacteria
_version_	1718383772165996544

Tigecycline activity against metallo-β-lactamase-producing bacteria

Ejemplares similares